FDA Targets GLP 1 and Peptide Compounding, Advertising and 'Research Use Only' Labeling Multifunctionality and Possible Medical Application of the BPC 157 PeptideLiterature and Patent Review The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York FDA to weigh easing limits on unproven peptides promoted by RFK Jr.